NDAORALTABLET
Approved
Sep 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ATACAND HCT (candesartan cilexetil and hydrochlorothiazide) by ANI Pharmaceuticals is mechanism of action angiotensin ii is formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme (ace, kininase ii). First approved in 2000.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATACAND HCT is a fixed-dose combination of candesartan cilexetil (angiotensin II receptor blocker) and hydrochlorothiazide (thiazide diuretic) for oral treatment of hypertension. It works by blocking angiotensin II-mediated vasoconstriction and aldosterone secretion while simultaneously reducing plasma volume through diuretic action. The dual mechanism provides complementary blood pressure reduction with potassium-sparing effects.
$0.609MPart D
LOE ApproachingDeclining
Product approaching end-of-life with minimal Part D utilization (1,002 claims in 2023); team size likely contracted with focus on managed decline and generic transition support.
Mechanism of Action
Mechanism of Action Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and…
Worked on ATACAND HCT at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.